<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84641">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02003365</url>
  </required_header>
  <id_info>
    <org_study_id>FX006-2013-005</org_study_id>
    <nct_id>NCT02003365</nct_id>
  </id_info>
  <brief_title>Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flexion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flexion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an open-label, single administration design, conducted in patients with
      OA of the knee.

      Patients will be enrolled sequentially with 8 to 10 patients per Cohort as follows:

      Cohort A: FX006 40 mg, Final Visit at Week 20 Cohort B: FX006 40 mg, Final Visit at Week 16
      Cohort C: FX006 10 mg, Final Visit at Week 12 Cohort D: FX006 40 mg, Final Visit at Week 12
      Cohort E: Triamcinolone acetonide immediate-release (TCA IR) 40 mg, Final Visit Week 12

      Each patient will be evaluated for up to 12, 16 or 20 weeks following a single
      intra-articular (IA) injection of FX006 at 10 mg or 40 mg or TCA IR 40 mg, depending on the
      assigned Cohort. Following the screening visit, safety will be evaluated at three (3)
      out-patient visits and synovial fluid will be collected at Day 1 for baseline measurements
      and the Final Visit for drug concentration measurements.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the concentration of triamcinolone acetonide in synovial fluid</measure>
    <time_frame>12 to 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>12 to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>FX006 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FX006 10 mg, single IA injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX006 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FX006 40 mg single IA injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCA IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TCA IR 40 mg single IA injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FX006 10 mg</intervention_name>
    <arm_group_label>FX006 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FX006 40 mg</intervention_name>
    <arm_group_label>FX006 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCA IR 40 mg</intervention_name>
    <arm_group_label>TCA IR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Written consent to participate in the study

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Has documented diagnosis of OA of the index knee made at least 6 months prior to
             Screening

          -  Currently meets American Collage of Rheumatology Criteria (clinical and radiological)
             for OA

          -  Index knee pain for &gt;15 days over the last month

          -  Body mass index (BMI) â‰¤ 40 kg/m2

          -  Ambulatory and in good general health

        Key Exclusion Criteria:

          -  History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
             spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis or
             amyloidosis

          -  History of arthritides due to crystals (e.g., gout, pseudogout)

          -  History of infection in the index joint

          -  Clinical signs and symptoms of active knee infection or crystal disease of the index
             knee

          -  Presence of surgical hardware or other foreign body in the index knee

          -  Unstable joint (such as a torn anterior cruciate ligament) within 12 months of
             Screening

          -  IA corticosteroid (investigational or marketed) in any joint within 6 months of
             Screening

          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
             Screening

          -  Oral corticosteroids (investigational or marketed) within 1 month of Screening

          -  Inhaled, intranasal and topical corticosteroids (investigational or marketed) within
             2 weeks of Screening

          -  Any other IA investigational drug/biologic within 6 months of Screening

          -  Prior use of FX006

          -  Prior arthroscopic or open surgery of the index knee within 12 months of Screening

          -  Planned/anticipated surgery of the index knee during the study period

          -  Active or history of malignancy within the last 5 years, with the exception of
             resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected
             cervical atypia or carcinoma in situ
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ducansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 10, 2015</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <firstreceived_results_disposition_date>August 10, 2015</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>steroids</keyword>
  <keyword>FX006</keyword>
  <keyword>triamcinolone acetonide</keyword>
  <keyword>synovial fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
